A Phase 1 interventional study of Flortaucipir F18 and Brain PET scan in Alzheimer's Disease, sponsored by Avid Radiopharmaceuticals. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-10.
Sponsored by Avid Radiopharmaceuticals (part of Eli Lilly and Company) · Phase 1, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing flortaucipir in Alzheimer Disease — 4 open to participants now, 4 under way, none of them phase 3. flortaucipir · Alzheimer Disease.
Among the 22 studies testing flortaucipir in Alzheimer Disease, this one is the 15th largest by enrollment, is one of 4 that started in 2015, is one of 10 in phase 1, and was the 5th registered.
3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →4 of the 22 studies testing flortaucipir in Alzheimer Disease are open now, in 2 countries. Recruiting first, the newest first:
Eli Radiopharma · Sites in China
Ages 50–85 · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 50+ · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 60+ · Women only · Healthy volunteers
Mayo Clinic · Sites in United States
Ages 21–80
By country, each count listing its studies:
flortaucipir: first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 7 · Phase 3 4 · Phase 4 1
First in 2013; this study’s year is marked. 4 started in 2015.
This study's enrollment of 35 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 70 across the 22 interventional studies. Of the 17 that completed or were terminated, 15 (88%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
This study is registered under Avid Radiopharmaceuticals, one of the names counted as Eli Lilly and Company. Under that name alone:
Avid Radiopharmaceuticals is the lead sponsor of 54 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.
99 studies in Alzheimer Disease by Eli Lilly and Company: 13 open now, 19 under way, 8 of them phase 3. Of 79 finished, 61 (77%) have results posted.
Among the 99 studies in Alzheimer Disease by Eli Lilly and Company, this one is the 73rd largest by enrollment of the 95 interventional ones that give a count, is one of 5 that started in 2015, is one of 34 in phase 1, and was the 52nd registered.
Eli Lilly and Company’s Alzheimer Disease studies by the year they started, since 2002.
2 of the studies testing flortaucipir in Alzheimer Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07580703Eli RadiopharmaA Phase I Study of [18F]Flortaucipir PET Imaging in Chinese Subjects: Safety, Pharmacokinetics, Biodistribution, Radiation Dosimetry, and Preliminary Diagnostic Efficacy | 2026-12-31 |
| NCT02740634Mayo ClinicMolecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study | 2027-03 |
Add all 2 to your calendar (.ics) → With an account.
Among the 22 studies testing flortaucipir in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 99 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
Subjects enrolled in the Professional Fighters Brain Health Study (PFBHS) will receive flortaucipir to explore its use as a biomarker for brain injury related to repetitive head trauma and to examine the relationship between clinical presentation and tau deposition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All Subjects
Subjects with cognitive impairment
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
Drug: Flortaucipir F18 · Procedure: Brain PET scan
Retired professional fighters (with and without cognitive impairment) receiving a flortaucipir PET scan
Drug: Flortaucipir F18 · Procedure: Brain PET scan
IV injection, 370 megabecquerel (MBq) (10 mCi)
Also known as: [F-18]T807, 18F-AV-1451, LY3191748, Tauvid
positron emission tomography (PET) scan of the brain 75-105 minutes post injection
Flortaucipir Imaging (Quantitative) Between Cognitive Groups
Standard Uptake Value Ratio (SUVr) by subject enrollment group (cognitive impaired/normal) across weighted cortical average, frontal, temporal, parietal, and occipital brain regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
Time frame: baseline scan
Flortaucipir Imaging (Quantitative) Between Fighter Groups
Standard Uptake Value Ratio (SUVr) by subject enrollment group (active fighter/retired fighter) across weighted cortical average, frontal, temporal, parietal, and occipital brain regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
Time frame: baseline scan
Flortaucipir Imaging (Qualitative) Between Cognitive Groups
Qualitative read results (no, mild, moderate, or intense uptake) compared between cognitively impaired (CI) and cognitively normal (CN) groups.
Time frame: baseline scan
Flortaucipir Imaging (Qualitative) Between Fighter Groups
Qualitative read results (no, mild, moderate, or intense uptake) compared between active and retired fighter groups
Time frame: baseline scan
Enrollment occurred between Feb 2015 and Feb 2017
| Milestone | Active Professional Fighters | Retired Professional Fighters |
|---|---|---|
| Started | 12 | 23 |
| Flortaucipir pet scan | 10 | 20 |
| Completed | 8 | 20 |
| Not completed | 4 | 3 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: <10 professional fights | 2 | 0 |
Standard Uptake Value Ratio (SUVr) by subject enrollment group (cognitive impaired/normal) across weighted cortical average, frontal, temporal, parietal, and occipital brain regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
| standardized uptake value ratio (SUVr) | Cognitively Impaired Fighters | Cognitively Normal Fighters |
|---|---|---|
| Weighted cortical average | 1.0048 (0.977 to 1.0327) | 0.971 (0.9401 to 1.002) |
| Frontal | 0.9731 (0.9394 to 1.0068) | 0.9357 (0.8983 to 0.9732) |
| Temporal | 0.9867 (0.9425 to 1.0309) | 0.9305 (0.8812 to 0.9797) |
| Parietal | 0.9472 (0.9097 to 0.9847) | 0.9288 (0.8871 to 0.9705) |
| Occipital | 0.9513 (0.912 to 0.9906) | 0.9247 (0.8809 to 0.9684) |
Standard Uptake Value Ratio (SUVr) by subject enrollment group (active fighter/retired fighter) across weighted cortical average, frontal, temporal, parietal, and occipital brain regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.
| standardized uptake value ratio (SUVr) | Active Professional Fighters | Retired Professional Fighters |
|---|---|---|
| Weighted cortical average | 0.9965 (0.963 to 1.0299) | 0.9794 (0.9546 to 1.0042) |
| Frontal | 0.9816 (0.9411 to 1.022) | 0.9273 (0.8973 to 0.9572) |
| Temporal | 0.9838 (0.9306 to 1.0369) | 0.9334 (0.894 to 0.9728) |
| Parietal | 0.9623 (0.9172 to 1.0073) | 0.9137 (0.8803 to 0.9471) |
| Occipital | 0.9632 (0.916 to 1.0105) | 0.9127 (0.8777 to 0.9478) |
Qualitative read results (no, mild, moderate, or intense uptake) compared between cognitively impaired (CI) and cognitively normal (CN) groups.
| Participants | Cognitively Impaired Fighters | Cognitively Normal Fighters |
|---|---|---|
| No Uptake | 16 | 12 |
| Mild Uptake | 2 | 0 |
| Moderate Uptake | 0 | 0 |
| Intense Uptake | 0 | 0 |
Qualitative read results (no, mild, moderate, or intense uptake) compared between active and retired fighter groups
| Participants | Active Professional Fighters | Retired Professional Fighters |
|---|---|---|
| No Uptake | 10 | 18 |
| Mild Uptake | 0 | 2 |
| Moderate Uptake | 0 | 0 |
| Intense Uptake | 0 | 0 |
Collected over End of study for AE reporting was 48 hours after the last study drug administration.. Non-serious events are listed at a 1.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Active Professional Fighters | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| Retired Professional Fighters | 0/20 (0%) | 0/20 (0%) | 2/20 (10%) |
| Event | Active Professional Fighters | Retired Professional Fighters |
|---|---|---|
| diarrhoeaGastrointestinal disorders | 0/10 | 1/20 |
| epistaxisRespiratory, thoracic and mediastinal disorders | 0/10 | 1/20 |
Only includes subjects who received a flortaucipir PET scan in the study.
| Age, Continuous(years) | Active Professional Fighters | Retired Professional Fighters | Total |
|---|---|---|---|
| Mean | 31.7 ± 4.27 | 47.6 ± 10.21 | 42.3 ± 11.49 |
| Sex: Female, Male(Participants) | Active Professional Fighters | Retired Professional Fighters | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 10 | 20 | 30 |
| Ethnicity (NIH/OMB)(Participants) | Active Professional Fighters | Retired Professional Fighters | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 9 | 10 |
| Not Hispanic or Latino | 9 | 11 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Active Professional Fighters | Retired Professional Fighters | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 5 | 7 | 12 |
| White | 3 | 13 | 16 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Other | 2 | 0 | 2 |
| Region of Enrollment(participants) | Active Professional Fighters | Retired Professional Fighters | Total |
|---|---|---|---|
| United States | 10 | 20 | 30 |
| Amyloid status(Participants) | Active Professional Fighters | Retired Professional Fighters | Total |
|---|---|---|---|
| Amyloid negative | 1 | 14 | 15 |
| Amyloid positive | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2015 to primary completion in Feb 2017, 23 months.
Results were first posted in Sep 2020, 3 years 7 months after primary completion.
Of 161 industry-sponsored phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 23 months is above that.
Counting every sponsor, half of 234 studies reached it within 18 months; a quarter within 7 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Flortaucipir